CRC tissues; adjacent normal tissues; xenografted tumor tissues; lung tissues
HT29; SW480; HCT116; RKO; SW620; NCM460
cell line-derived xenograft
other pathway/process (promotes); p53 signaling (inhibits); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); apoptosis (inhibits); ceRNA regulation (other); lipid metabolism (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; ChIP / ChIP-seq; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Survival Analysis; Bioinformatics Analysis
High circACACA expression is associated with larger tumor size, advanced TNM stage, tumor metastasis, lymph node metastasis, and shorter overall survival; circACACA is proposed as a prognostic marker and therapeutic target for CRC.
circACACA is upregulated in colorectal cancer tissues and cell lines and is associated with advanced clinicopathological features and poor overall survival. Functionally, it promotes CRC proliferation, migration, invasion, tumor growth and metastasis while suppressing apoptosis. Mechanistically, circACACA sponges miR-193a-3p and miR-193b-3p to increase HDAC3, reduce p53 acetylation/transcriptional activity, and activate the MVA pathway.
0.8912
Circular RNA ACACA negatively regulated p53-modulated mevalonate pathway to promote colorectal tumorigenesis via regulating miR-193a/b-3p/HDAC3 axis.
combined biological and clinical study